

98TH ADVISORY FORUM
KONGENS LYNGBY, 03-04 DECEMBER 2025

MICROBIOMES IN REGULATORY SCIENCE- EMERGING CHALLENGES AND REGULATORY READINESS

Konstantinos Paraskevopoulos (EFSA
Chief Scientist Office and the KIC
BIOTECHNOLOGY)



OUTLINE



WHY MICROBIOME & WHY NOW?
Strategic context & the challenge

ARE WE PREPARED? Taking stock


EFSA'S RESPONSE Addressing the gaps

THE PATH FORWARD Joining Forces



MICROBIOME-RELEVANT SCIENTIFIC AREAS

Microbiomes relevant to many EFSA domains



MICROBIOME: A STRATEGIC EU (& INTERNATIONAL) PRIORITY



EU policy Framework

Microbiome-based solutions/innovations promoted by:

- Life Sciences Strategy 2025
- Bioeconomy Strategy
- Food 2030
- Several EU Horizon projects



EU Health Regulation

- **SoHO Regulation** (taking effect in 2027)
- **Microbiome-based live biotherapeutic products** (European Medicines Agency (EMA)) has received first application)



INTERNATIONAL

FAO

- Microbiome-based solutions for sustainable agrifood & nutrition, food safety, chemical risk assessment


US FDA

- Establishing regulatory science focus areas for microbiome products

Cross-sectoral momentum signals increasing risk assessment needs across multiple product categories



MICROBIOME PRODUCTS PIPELINES- STRONG PUSH FOR INNOVATION



Microbiome-based products market is growing rapidly (GMI, June 2025)



💡 Multiple types: challenging FWs

- ❑ CEPs: Competitive exclusion Products as Feed additives
- ❑ Fermented Products: Undefined communities
- ❑ Novel foods: multi strains, Akkermansia
- ❑ Biopesticides: microbial consortia

⚠️ Current Situation

- ❑ Products being/are developed
- ❑ Applications submitted soon?
- ❑ Risk assessment frameworks fit for purpose?



MICROBIOME-BASED PRODUCTS-FOOD & FEED EXAMPLES



Competitive exclusion products (CEPs) as feed additives

- **Composition:** Microbiome material from poultry cecum
- **Benefit** Prevents pathogen colonisation
- **Status:** Already developed



Complex Fermented Products

- **Composition:** Multi Strain complex probiotic drinks, wild fermentation beverages
- **Benefit** Marketed as food supplements with health claims
- **Status;** Already developed



Common challenges

- Undefined microbial communities/composition
- Genome screening (AMR, Pathogen detection, etc)
- Interactions with host microbiome
- Community functional effects and stability unclear



FRAMEWORK NEEDED

- Characterisation methods
- Safety screening methods
- Host interaction assessment
- Functional evaluation tools



WHY CURRENT FRAMEWORKS ARE INSUFFICIENT

Current Frameworks

✓ What Works

- Single strain
- Culturable organisms
- Traditional identification methods
- Individual/few strain safety criteria
- Established approaches

VS

Microbiome Products

✗ What Doesn't Work

- Undefined complex microbial communities
- Non culturable organisms
- Unknown community interactions/effects
- Dynamic ecosystems
- No established frameworks

Regulatory gap highlighted: New EFSA Microbiology Guidance (2025) - Standardised frameworks needed for products containing/produced from complex communities & recipient ecosystems



EFSA PREPARATORY WORK (BUILDING THE FOUNDATION)-ROADMAPS FOR ACTION 2024




HUMAN & ANIMAL GUT MICROBIOME

- Xenobiotics effects on gut microbiome
- Health outcomes assessment
- Critical gaps identified for regulatory science



ENVIRONMENTAL MICROBIOMES

- Soil, water, plants etc microbiomes
- One Health connections
- Food safety implications



**Systematic Gap analysis →
Coordinated action needed**



OMICS TECHNOLOGIES

- Metagenomics and other Omics for microbial characterisation
- Regulatory application framework



CRITICAL KNOWLEDGE GAPS IDENTIFIED

01



Identity, Functional & Stability Characterisation

Cannot **identify/characterise** all organisms in complex mixtures/products.

02



In Vitro Models

No **standardised/validated** systems for testing microbiome products

03



Causality, AOPs & Mechanisms

Cannot establish **cause effect relationships** for microbiome changes

04



Biomarkers

No **validated** markers linking microbiome changes to health outcomes

05



Population Baselines

Insufficient **reference data** for “normal” vs “harmful”- microbiome variation

06



Safety Frameworks

No frameworks for **complex mixtures** level safety assessment.

-  Methodological
-  Understanding
-  Frameworks


Additional important gaps



XENOBIOTICS EXPOSURE–MICROBIOME: ANOTHER IMPORTANT ANGLE



Gut Microbiome
roadmap



Food additives, pesticides, contaminants

MEMBER STATES ACTIVITIES/CAPACITY

JOINING FORCES INITIATIVE

- Focal Point Outreach: "What microbiomes-related work is happening in your Country?"
- Bilaterals with member states

14

Member States
With documented activity
or interest

4

Supporting EU Framework

5

Regulatory Science Active

Three Levels of Engagement

Tier 1

REGULATORY FRAMEWORKS

- **Italy** – National Framework Proposal
- **Poland** – Long standing experience, Calls for EU FW
- **Germany** – Microbiome data assessment pipeline

Tier 2

ACTIVE PROGRAMS

- **Denmark** - Xenobiotic RA
- **Netherlands** -EU-wide reference database/EU vision
- **Cyprus** – Feed & soil health projects

Tier 3

RA GAP + RESPONSE

- **Lithuania** - Regulatory gap for fermented multi strain products, developing criteria

KEY MS CONTRIBUTIONS & CALLS FOR ACTION

Poland

Specific Recommendations to EFSA:

Standard procedures for microbiome RA

Data/methodology exchange platform

~20 years capacity 3 institutions / Advanced omics

Germany

Automated Pipeline for possible EU-Wide Use:

- Developing microbiome data assessments
- Pathogen detection, virulence, AMR genes
- Microbiome-food interactions

EFSA ADME4NGRA collaboration

Italy

ISS 2025 Report- National FW tailored to EFSA work

- Methodologies for systematic inclusion
- One Health integration across domains

5 active IIZZSS projects / EUPAHW partnership

Lithuania

Request for EU-level Guidance for novel complex microbial products

Active National Response:

- National project developing microbiological criteria & advanced methods (e.g. Omics)
- Explicit request for EFSA guidance

Baltic region issue / Metagenomics/metabolomics approach

INTERNATIONAL ACTIVITIES & COORDINATION

Global efforts building microbiome regulatory science capacity



FAO

OH/REGULATORY

Soil & gut microbiome work, xenobiotic assessments (JECFA, JMPR), policy, capacity building



WHO

STANDARDS

International Reference Reagents, methodology harmonisation, quality standards



US FDA

REGULATORY

Standardised methodologies, regulatory science focus areas



Health Canada

TESTING

Testing platforms for microbial mixtures, safety assessment methods



World Microbiome Partnership

COORDINATION

Global platform for research coordination, knowledge exchange



EFSA PROJECT CALL 1: METAGENOMICS FOR COMPLEX MICROBIAL MIXTURES AS REGULATED PRODUCTS



EFSA RESPONSE: KIC Biotechnology led activities to prioritise knowledge gaps and propose **two Projects** to address some key gaps



Project Objective

Develop **fit-for-purpose metagenomics protocols** and **analytical frameworks** for characterising and assessing safety of complex microbial mixtures as regulated products

Gap addressed:

Traditional microbiological characterisation approaches are primarily designed for single organisms, creating a methodological gap for products with complex multi-species products



Budget
€ 1.25 M



Timeline
1.5 yrs



Case study
CEPs



Call launch
Jan/Feb 2026

KEY DELIVERABLES

- Standardised metagenomics protocols
- Safety screening methods (AMR, virulence, pathogens)
- Technical recommendations for data interpretation

IMPACT

- Facilitates assessment of **Competitive Exclusion Products (CEPs)** as feed additives
- Supports microbiology RA guidance
- Foundation for broader metagenomics adoption in RA



EFSA PROJECT CALL 2: MICROBIOME BIOMARKERS FOR RISK ASSESSMENT



Project Objective

Develop foundational methodological elements for integrating biomarker data into RA frameworks, supporting evaluation of dietary compounds and products effects on gut microbiome and host health

Gap Addressed :

Lack of fit for purpose biomarkers and in vitro models to assess dietary effects on microbiome and host health



Budget
€ 1.3 M



Timeline
3 yrs



Case study
Selected xenobiotics



Call launch
Feb/Mar 2026

1

Phase 1 € 300K; 1 year Systematic Meta-Analysis

- Systematic biomarkers review
- Assess in vitro model capabilities
- Define optimal biomarker-model pairings
- Identify analytical methods

Milestone: Go/No-Go decision for Phase 2 based on findings

2


Phase 2 € 1M; 2 years Experimental Testing

- Test prioritised biomarker-model combinations
- Assess microbiome & host responses
- Generate RA relevant data

Outcome: Technical recommendations for RA implementation



KNOWLEDGE GAP COVERAGE: PROGRESS ASSESSMENT



✓ Addressed (3)

Characterisation: Metagenomics protocols (P1)

Biomarkers: Validated endpoints (P2)

In Vitro Models: Model validation (P2)

● Partially Addressed (2)

Causality, AOPs & Mechanistic: e.g. dose-response, mechanistic FW remain (P2)

Safety Frameworks: CEPs enabled; broader product frameworks needed (P1)

X Not Addressed (6)

Important gaps: Population Baselines & Variability • Data Standards, Harmonisation & Reference DBs • In Vivo Validation • Functional/Efficacy Assessment • Long-term Effects & Persistence • In Silico Predictive Models



POSSIBLE COLLABORATION OPPORTUNITIES



EFSA Project Calls

Apply to metagenomics and biomarkers project Calls




Technical Discussion Group Creation

Expert exchange (e.g. on methodology, data standards. share information on various projects) and coordination



Workshop/Colloquium

Focused meeting on specific technical topics (co-planned/scoped by discussion group)




Joint Future Projects

Joint (co-funded?) regulatory science initiatives, share resources



WHAT IS NEXT – PRESENTATION QUESTIONS & TIMELINE





Why Work Together Now?



Products arriving before frameworks ready



Critical gaps require MS collaboration



Shared benefit across EU regulatory system



International momentum building globally

Thank you

contact: konstantinos.paraskevopoulos@efsa.europa.eu



STAY CONNECTED

SUBSCRIBE TO

efsa.europa.eu/en/news/newsletters

efsa.europa.eu/en/rss

[Careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



FOLLOW US ON BLUESKY

[@efsa.bsky.social](https://bsky.app/profile/efsa.bsky.social)

[@efsa-animals.bsky.social](https://bsky.app/profile/efsa-animals.bsky.social)

[@efsa-plants.bsky.social](https://bsky.app/profile/efsa-plants.bsky.social)



FOLLOW US ON INSTAGRAM

[@one_healthenv_eu](https://www.instagram.com/one_healthenv_eu)



LISTEN TO OUR PODCAST

Science on the Menu – Spotify, Apple Podcast and YouTube



FOLLOW US ON LINKEDIN

[Linkedin.com/company/efsa](https://www.linkedin.com/company/efsa)



CONTACT US

efsa.europa.eu/en/contact/askefsa

